LL28 effectively inhibits both IGF1R- and Src-dependent signaling pathways and has promising therapeutic potential in vitro against a panel of non-small cell lung cancer (NSCLC) cell lines and in vivo in tumor xenograft and mutant Kras-driven lung tumorigenesis models with marginal toxicity. The gene discussed is IGF1R; the disease is neoplasm.